Patients with type 1 and type 2 CALR mutations have different prognoses, and previously it was reported that MPN patients with type 1 CALR mutation but not type 2 CALR mutations had a better prognosis than those with JAK2 mutations [21]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.